MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2026.1743111

Медицинская библиотека · Frontiers in endocrinology · 2026

The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function.

Manzo Alessandro, Grassi Elisa Stellaria, Borghi Maria Orietta, Colombo Carla, Persani Luca, Cirello Valentina

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Tyrosine kinase inhibitors represent the most effective and long-lasting treatment currently available for aggressive thyroid cancers, but in some patients the response is poor or absent. Recently, we demonstrated that the response to Lenvatinib is associated with alterations in TP53 gene or protein. Aiming to find a novel therapeutic strategy for aggressive thyroid cancers, we investigated in vitro the DNA damage response pathway, where p53 plays a crucial role, and tested its inhibition through synthetic lethality or stress sensitization strategies.

METHODS

The DNA damage response has been characterized in a panel of p53-defective or proficient thyroid cancer cell lines both at basal level and in response to Doxorubicin, a DNA damaging agent, by western blot, immunofluorescence and MTT-based cell viability assay. We then evaluated the effect of a selective CHK1 kinase inhibitor, Prexasertib, either alone or in combination with Doxorubicin. Cell cycle variations and cell death were evaluated by flow-cytometry.

RESULTS

The p53-defective thyroid cancer cells showed a higher degree of genomic instability and, in response to Doxorubicin, activated not only ATM/CHK2 but also ATR/CHK1 to bypass p53 and induce DNA repair. We found that Prexasertib was more effective in p53-defective cells, since it significantly reduced tumor cell proliferation due to replicative failure and cell death. Moreover, Doxorubicin potentiated the Prexasertib effects in p53-defective thyroid cancer cells, yet at the lowest doses.

CONCLUSIONS

This study unravels the potential of Prexasertib as a novel treatment option for aggressive thyroid cancers p53-defective and poorly responsive to tyrosine kinase inhibitors.

Для цитирования: Manzo Alessandro, Grassi Elisa Stellaria, Borghi Maria Orietta, Colombo Carla, Persani Luca, Cirello Valentina. The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function.. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1743111.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.